⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 13, 2024HaemophiliaOpen Access

Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients

Dagmar M. Hajducek Pierre Chelle Alfonso Iorio Emma Iserman Andrea N. Edginton

View Full Paper

Ask AI

Bookmark

Share

Abstract

Web-Accessible Population-Pharmacokinetic Service-Haemophilia (WAPPS-Hemo) data are available to study factor-concentrate usage, defined as the required weekly dose to achieve a 3% trough (WD3T), across standard and extended half-life (SHL/EHL) products.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hajducek et al. (2024) studied this question.

synapsesocial.com/papers/68e6a630b6db643587629b94 https://doi.org/10.1111/hae.15032

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Use of Extended Half-Life Factor IX in Children with Haemophilia B2025
2Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxisOriginal Research · 2016 · 62 citations
3Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AOriginal Research · 1997 · 118 citations
4Extended Half-Life Factor Concentrates in Haemophilia TreatmentClinical Trial · 2026 · 1 citations
5Population Pharmacokinetics of Plasma‑Derived Factor X Using Clotting and Chromogenic Assays: A WAPPS‑Hemo ModelOriginal Research · 2026

More related papers

A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study2025
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform2024
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?2021

More from Haemophilia

Association of TNFAIP3 Polymorphisms With Bleeding Phenotypes and FVIII Inhibitor Development in Patients With Hemophilia A: A Case‐Control StudyWed,
100 Years of von Willebrand Disease (VWD): Comparison of Historical and Contemporary von Willebrand Factor (VWF) Activity Assays in the Laboratory Identification of VWDMon,